Government Shutdown Poised to Become Longest in U.S. History
P.M. Edition for Nov. 4. WSJ’s Congress reporter Katy Stech Ferek talks about the latest in negotiations as lawmakers search for a deal to end the shutdown. Spencer Jakab, who writes WSJ’s Markets A.M. newsletter, explains why a famous method of valuing stocks suggests rough years ahead. And it’s Election Day in the U.S. Head to WSJ’s live blog for more coverage of key races in New York City, New Jersey and Virginia. Sabrina Siddiqui hosts.
Sign up for the WSJ's free What's News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
--------
12:29
--------
12:29
What’s News in Earnings: Who Is Winning the Obesity-Drug Arms Race?
Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump’s drug-pricing plans, including TrumpRx.
WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies’ earnings reports and analyst calls to find out what’s going on under the hood of the American economy.
Sign up for the WSJ's free Markets A.M. newsletter.
Further Reading:
Novo Nordisk Sweetens Offer for Metsera - WSJ
Pfizer Sues Seeking to Block Novo Nordisk’s Effort to Undo Weight-Loss Drug Deal
Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk
The Day Pharma’s Weight-Loss Gold Rush Intensified
Pfizer Profit Falls Amid Lower Covid-19 Drug Demand
Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera
Novo Nordisk to Shake Up Board After Obesity-Market Challenges
Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings
AbbVie Lifts Profit Outlook as Sales Rise
Bristol Myers Squibb Profit Soars, Raises Revenue Guidance
Merck Profit Rises on Strong Keytruda Demand
GSK Lifts Guidance After Specialty Medicines Boost Sales
Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead
Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise
J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains
Learn more about your ad choices. Visit megaphone.fm/adchoices
--------
7:47
--------
7:47
Trump Backs Cuomo in New York Mayoral Race
A.M. Edition for Nov. 4. It is election day with voters heading to the polls in states including New York, Virginia and New Jersey. WSJ’s John McCormick says that although Democrats are expected to win all three races, it will not necessarily ease the divided party’s troubles. Plus, WSJ’s Gavin Bade says there is a lot at stake for President Trump as his tariffs are set to go before the Supreme Court. And two major investors reject Elon Musk’s $1 trillion pay deal. Caitlin McCabe hosts.
Sign up for the WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
--------
14:39
--------
14:39
What Drove Kimberly-Clark’s $40 Billion Deal for Tylenol Maker Kenvue
P.M. Edition for Nov. 3. In one of the biggest takeovers of the year, Kimberly-Clark has agreed to buy Tylenol maker Kenvue for more than $40 billion. WSJ business reporter Natasha Khan joins to discuss the strategy behind the deal. Plus, Chipotle has invested heavily in courting younger customers. Now, they’re feeling the economic pinch—and so is Chipotle. Journal reporter Heather Haddon talks about what the company is doing about it. And Mali may soon be the first country to fall to al Qaeda. We hear from WSJ security correspondent Benoit Faucon on what that would mean for the U.S.-designated terrorist group’s presence in Africa. Alex Ossola hosts.
Sign up for the WSJ's free What's News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
--------
14:52
--------
14:52
Shutdown Nears Record as Crucial Week Begins
A.M. Edition for Nov. 3. Democrats are pressing President Trump to come to the table as the government shutdown nears a record 35 days. Plus, WSJ’s Chelsey Dulaney breaks down why Europe’s former economic heavyweights are falling behind their southern neighbors. And we dig into the surprising comeback of one of the housing market’s riskiest loans — and why homebuyers are taking the gamble. Caitlin McCabe hosts.
Sign up for the WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
What's News brings you the biggest news of the day, from business and finance to global and political developments that move markets. Get caught up in minutes twice a day on weekdays, then take a step back with our What’s News in Markets wrap-up on Saturday and our What’s News Sunday deep dive.
New Zealand